Who are Control group: Oxiracetam Injection's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): CDP-Choline, L-Alpha glycerylphosphorylcholine, Test group: L-oxiracetam Injection.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/control-group-oxiracetam-injection.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Control group: Oxiracetam Injection — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Control group: Oxiracetam Injection (Control group: Oxiracetam Injection) competitive landscape: 3 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Nootropic agent. Area: Neurology.

phase 3 Nootropic agent Neurology Small molecule Live · refreshed every 30 min

Target snapshot

Control group: Oxiracetam Injection (Control group: Oxiracetam Injection) — Nanjing Yoko Biomedical Co., Ltd.. Oxiracetam enhances neuronal membrane fluidity and increases oxygen utilization in the brain, promoting cognitive function and neuroprotection.

Comparator set (3 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Control group: Oxiracetam Injection TARGET	Control group: Oxiracetam Injection	Nanjing Yoko Biomedical Co., Ltd.	phase 3	Nootropic agent
CDP-Choline	CDP-Choline	Patricia M. Arenth	marketed	Nootropic agent / Neuroprotective	Phosphatidylcholine synthesis pathway
L-Alpha glycerylphosphorylcholine	L-Alpha glycerylphosphorylcholine	Clinical Institute of the Brain, Russia	phase 3	Nootropic agent / Cholinergic precursor	Acetylcholine synthesis pathway; phosphatidylcholine metabolism
Test group: L-oxiracetam Injection	Test group: L-oxiracetam Injection	Nanjing Yoko Biomedical Co., Ltd.	phase 3	Nootropic agent / Pyrrolidone derivative

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Nootropic agent class)

Nanjing Yoko Biomedical Co., Ltd. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Control group: Oxiracetam Injection — Competitive Intelligence Brief. https://druglandscape.com/ci/control-group-oxiracetam-injection. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab